Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01824602
Other study ID # BIA-2093-204
Secondary ID
Status Terminated
Phase Phase 2
First received March 28, 2013
Last updated February 26, 2014
Start date February 2006
Est. completion date November 2006

Study information

Verified date August 2013
Source Bial - Portela C S.A.
Contact n/a
Is FDA regulated No
Health authority Spain: Spanish Agency of Medicines
Study type Interventional

Clinical Trial Summary

The primary study objective was to evaluate the dose-dependent efficacy of eslicarbazepine acetate administered at doses of 600, 1200, and 1800 mg over a 3-week period, compared with placebo, as therapy in patients with acute mania. The secondary objectives of this study were to a) evaluate the safety and tolerability of eslicarbazepine acetate (BIA 2-093) administered at doses of 600, 1200, and 1800 mg compared with placebo, b) assess the duration to onset of action in the different dose groups, and c) monitor the appearance of depressive symptoms.


Description:

This was a phase II, double-blind, fixed multiple dose, randomised, placebo-controlled, multicentre clinical trial in patients with a diagnosis of bipolar I disorder who experienced an acute manic (including mixed) episode. Patients who met the selection criteria at randomisation visit (V) (V2, Day 1) were randomised to 1 of 4 treatment groups: 600, 1200, or 1800 mg eslicarbazepine acetate, or placebo. Patients started the assigned treatment on Day 1 and were followed for up to 3 weeks. On Day 10, patients who showed no improvement were switched to open-label escape therapy with an established antimanic therapy. Patients could have been hospitalized at screening or at any time during the study at the investigator's discretion. Following randomisation (V2, Day 1), patients were assessed on Days 3, 7, 10, 14, 21, 28, and 56, after which they could either enter a recurrence prevention study, or the study drug could be tapered off and they could undergo follow-up assessments.


Recruitment information / eligibility

Status Terminated
Enrollment 38
Est. completion date November 2006
Est. primary completion date November 2006
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Aged 18 years or more.

- A documented diagnosis of bipolar I disorder according to the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) criteria (i.e., 296.0, 296.4 or 296.6).

- Currently displaying an acute manic (including mixed) episode according to the DSM-IV criteria.

- A Young Mania Rating Scale (YMRS) total score of 20 or greater.

- Symptoms of the current manic episode starting within 2 weeks prior to Randomization (V2, Day 1).

- Able to undergo a standard evaluation, including clinical interview, ratings and laboratory studies.

- Signed informed consent form (ICF).

- Post-menopausal or otherwise incapable of becoming pregnant by reason of surgery or tubal ligation. In case of woman of childbearing potential, patient presents a serum pregnancy test consistent with a non-gravid state and will use double-barrier contraception until at least the post-study visit (PSV).

Exclusion Criteria:

- History of schizophrenia or schizoaffective disorder, psychotic features or rapid cycling.

- Currently treated with carbamazepine or oxcarbazepine.

- History of unresponsiveness, intolerance or hypersensitivity to related compounds (carbamazepine, oxcarbazepine or licarbazepine).

- Use of any depot-neuroleptics for the current manic episode

- Abuse of stimulating drugs or use of any systemic sympathicomimetic drug within the previous 2 weeks.

- Electroconvulsive therapy (ECT) within the previous 3 months

- History of dependence or chronic abuse from alcohol, drugs or medications within the last year.

- Judged clinically to be at risk of harm to self or others.

- Second or third-degree atrioventricular blockade not corrected with a pacemaker.

- Relevant ECG or laboratory abnormalities.

- Calculated creatinine clearance <30 ml/min [men: (140-age) x weight / serum creatinine x 72; women: (0.85) (140-age) x weight / serum creatinine x 72. Age in years, weight in kg, and serum creatinine in mg/dl].

- Pregnancy or nursing.

- Participation in other drug clinical trial within the last 2 months before Randomization visit

- Not ensured capability to perform the trial or to comply with the study protocol (e.g. mental retardation or severe inability to communicate);

- Any other uncontrolled clinically relevant disorder.

- Previous treatment with Eslicarbazepine Acetate.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Eslicarbazepine acetate 1800 mg
Eslicarbazepine acetate to be taken orally, was available as 600 mg tablets.
Eslicarbazepine acetate 1200 mg
Eslicarbazepine acetate to be taken orally, was available as 600 mg tablets.
Eslicarbazepine acetate 600 mg
Eslicarbazepine acetate to be taken orally, was available as 600 mg tablets.
Placebo
Placebo sugar pills

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Bial - Portela C S.A.

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Young Mania Rating Scale (YMRS) Total Score From Baseline Until the End of the 3-week Treatment Period The YMRS is used to assess disease severity in patients who have been previously diagnosed with mania and it has proven psychometric properties through 11 item multiple-choice diagnostic questionnaire and the total score is determined from the summation of each 11 individual scores (and can range from 0 - 60) based on the patient's subjective feedback of his clinical condition over the previous 48 hours. A higher score indicates a worse rating for symptoms related to mania. At every visit throughout the study, investigators administered the YMRS. The results of the primary analysis of efficacy were calculated using Analysis of covariance (ANCOVA) with Last Observation Carried Forward (LOCF). Primary variable is presented through ANCOVA results for absolute change in YMRS total score from baseline (V2) to end of treatment (V7). A responder has at least 50% improvement (reduction) in the YMRS total score or has a total score of less than 12 points at the end of treatment period. baseline and 3-week No
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03641300 - Efficacy of Convulsive Therapies for Bipolar Depression N/A
Withdrawn NCT01495156 - Study of the Efficacy of Adjunctive Lithium Treatment for the Treatment of Psychotic Mania Phase 4
Completed NCT00982020 - Study in Adolescents With Schizophrenia or Bipolar Disorder Phase 4
Completed NCT00746343 - Reducing Medical Risks in Individuals With Bipolar Disorder - Full Study N/A
Completed NCT00177463 - L-Carnosine for Bipolar I Disorder N/A
Completed NCT03257865 - A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes, Associated With Bipolar I Disorder Phase 3
Completed NCT03259555 - A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes Associated With Bipolar I Disorder Phase 3
Not yet recruiting NCT06433635 - Sequential Multiple Assignment Randomized Trial for Bipolar Depression Phase 4
Completed NCT04127058 - Evaluating a New Iloperidone Titration Scheme in Bipolar I Disorder or Schizophrenia Phase 1
Recruiting NCT05977023 - NMDA Receptor Modulation for the Treatment of Bipolar I Disorder Phase 2
Recruiting NCT05340686 - Braining- Aerobic Physical Activity as Add on Treatment in Bipolar Depression N/A
Completed NCT03287869 - A Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Participants With Bipolar I Disorder. Phase 3
Enrolling by invitation NCT04987229 - Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects Phase 3
Completed NCT00761761 - Sensoril(Ashwaganhda)for Bipolar Disorder Phase 3
Completed NCT00232414 - A Double-Blind Randomized Placebo Controlled Study of Quetiapine for the Treatment of Depression in Adolescents With Bipolar Disorder Phase 3
Completed NCT03292848 - Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to <13 Years Old) With Central Nervous System Disorders Phase 1
Active, not recruiting NCT04561622 - Emotional Proactive Processing in Bipolar Disorder
Recruiting NCT03943537 - Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients With Psychotic Disorders Phase 2
Completed NCT03334721 - Gabapentin for Bipolar & Cannabis Use Disorders Phase 2
Active, not recruiting NCT05658510 - Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III) Phase 3